We aren't just statistics. We are mothers, daughters, and friends. We are out of time, and we are demanding change from AstraZeneca Wes Streeting @nhsengland @DaiichiSankyoUK
#metupuk #breastcancernow #Enhertu #enhertunow #her2low

🧵1/2

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer | Docwire News Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.

Dr Sara Nunnery breaks down the evolving HER2 classification system and the clinical impact of DESTINY-Breast06. Hear how #Enhertu is reshaping treatment for HR+/HER2-low #BreastCancer. Watch now ⬇️ docwirenews.com/post/reclass... #HER2Low #DESTINYBreast06 #Oncology #CancerResearch

Improving HER2-Low Diagnosis in Metastatic Breast Cancer: Scoring System Enhances Precision | Docwire News A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.

A new HER2-low scoring system could help pathologists more accurately identify HER2-low metastatic breast cancer—potentially expanding patient access to HER2-targeted therapies.
🔗 www.docwirenews.com/post/improvi...
#BreastCancer #HER2low #CancerDiagnostics #OncTwitter @petermaccc.bsky.social

🚨 New Podcast 🚨

Dive into the evolving world of HER2-low expression in metastatic breast cancer.

🎙️ Join Prof. Fran Boyle & Dr. Sanjeev Kumar to unpack HER2 testing, patient comms & emerging therapies

🔗 Listen now: t.ly/jFmny #MedSky #OncSky #CanSky #OncologyPodcast #BreastCancer #HER2Low #HER2

The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype - npj Breast Cancer npj Breast Cancer - The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype

Immunohistochemistry v. Genomic Profiling: Game on for Her2Low. #her2low #genomictesting
Current breast cancer classification methods, particularly immunohistochemistry and PAM50, face challenges in accurately characterizing the HER2-low subtype, ... read more:
www.nature.com/articles/s41...

Check out this new study published in ESMO Open looking at clinical outcomes of early stage #TripleNegativeBreastCancer after neoadjuvant chemotherapy according to #HER2low status☆
www.sciencedirect.com/science/arti...
@ptarantinomd.bsky.social

But like everything else, there are side effects, mainly interstitial lung disease (aka one monitors or inflammation of the lungs). Nause can be pretty bad too, right @swaggsheila1? #HER2low #SABCS22 #bcsm

And why should we care? Because a ton of people who are classified as HER2- have 1+ or 2+ expression and could benefit from TDxD and maybe other HER2 targeted therapies. #HER2low #SABCS22 #bcsm

Starting off with THE hot topic: #HER2low. First, review of what HER2 overexpression means and what ADCs (anitibody-drug conjugates) do. DESTINY breast04 showed this can work even with low expression of HER2 (all BC cells have some HER2 receptors). #bcsm

First event (for me) at #SABCS22 is @abreastcancer/NBCC joint session on #HER2low where the last Kate Petrides was honored with a moment of silence. I think Kate would have preferred a moment of action. @metavivor #bcsm

Abstract 1052 Bao et al showed that those with HER2low ER+ MBC had a shorter PFS on endocrine therapy + CDK 4/6 inhibitor, compared to those with HER2=0 on IHC. #ASCO21 #bcsm #HER2low